LONDON, Sept. 27 /CNW/ - In the European Economic Area (EEA), the
practice of parallel trade in prescription medicines has been ongoing for more
than 40 years. At pharmacy buying prices, parallel trade in the top four
destination markets of the UK, Germany, Netherlands and Sweden totals more
than Euro2700 million.
It is no surprise then that the issue of parallel trade provokes
consistent hostility from pharmaceutical companies in Europe. Yet, despite
their efforts, the trade continues to flourish, eroding profits in the
freer-priced markets. Indeed, some might argue that it is precisely because of
failed efforts to stamp it out that parallel trade has grown to affect more
markets and more products than ever before.
In such an environment, it is therefore vital to coolly reassess strategy
and focus on proven techniques of tackling parallel trade that really can
maximise products' revenue. This can only follow from a detailed understanding
of the political, legal, economic and commercial environments in which the
trade occurs, and direct pre-emptive and reactive efforts at key targets.
A new 146-page report How to React to Parallel Trade, written by renowned
parallel trade expert Donald Macarthur and published by Scrip, provides the
information required to understand this complex and controversial issue. It
gives the reader essential background information, arguments for and against
parallel trade, explanation of the rules on bringing parallel imports to
market, lessons learnt from major controversies, country market profiles, and
predictions for the future of the practice.
Perhaps even more importantly, the report suggests strategic responses to
parallel trade and outlines their potential consequences. It also explains
price and supply management techniques and gives a number of recommendations
on how to tackle parallel trade both legally and successfully.
This exclusive, in-depth report is a must-read for any company involved
in the manufacture and supply of prescription medicines in Europe.
About the author
Donald Macarthur is a former secretary general of the European
Association of Euro-Pharmaceutical Companies (EAEPC), the pan-European
grouping of national associations and individual firms involved in parallel
trading of medicines. He has produced 40+ reports on pharmaceutical business
issues and his consultancy clients have included EFPIA, PhRMA and GIRP. He
worked for 16 years in the pharmaceutical industry and is listed in Marquis'
Who's Who in the World. He is considered by many to be the leading expert on
pharmaceutical parallel trade.
Scrip Reports publishes an extensive range of pharmaceutical therapeutic
market reports, detailed analyses of the pharmaceutical market for specific
geographic areas, in-depth profiles of companies operating in the industry,
financial and statistical analyses, directories and other strategic reports on
the healthcare sector.
Visit http://www.scripreports.com/paralleltrade for more information.
For further information:
For further information: Jenefer Trevena, Managing Editor, Scrip
Publishing, Tel: +44-(0)-20-7017-6989, Email: firstname.lastname@example.org; To
purchase How to React to Parallel Trade contact Andrew Maitland, Sales
Manager, Tel: +44-(0)-20-7017-6859, Email: email@example.com and
quote code JR20002P